PEPGEN INC. Share-based Payment Arrangement, Expense
PEPGEN INC. (PEPG) reported Share-based Payment Arrangement, Expense of $3.31 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-06
- PEPGEN INC. share-based payment arrangement, expense for the quarter ending 2026-06-30 was $3.31M, a 40.20% increase year-over-year.
- PEPGEN INC. share-based payment arrangement, expense for the quarter ending 2026-03-31 was $2.85M, a 16.81% decline year-over-year.
- PEPGEN INC. share-based payment arrangement, expense for the quarter ending 2025-12-31 was $2.44M, a 27.19% decline year-over-year.
- PEPGEN INC. share-based payment arrangement, expense for the quarter ending 2025-09-30 was $2.38M, a 26.32% decline year-over-year.
- PEPGEN INC. share-based payment arrangement, expense for fiscal 2025 was $10.61M, a 7.40% decline from fiscal 2024.
- PEPGEN INC. share-based payment arrangement, expense for fiscal 2024 was $11.46M, a 62.56% increase from fiscal 2023.
- PEPGEN INC. share-based payment arrangement, expense for fiscal 2023 was $7.05M, a 47.97% increase from fiscal 2022.
- PEPGEN INC. share-based payment arrangement, expense for fiscal 2022 was $4.76M, a 210.50% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.31M 10-Q · filed 2026-08-06 | $6.17M 10-Q · filed 2026-08-06 | $8.61M derived: sum of 3 quarters · filed 2026-08-06 | $10.98M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $2.85M 10-Q · filed 2026-05-12 | $5.29M derived: sum of 2 quarters · filed 2026-05-12 | $7.67M derived: sum of 3 quarters · filed 2026-05-12 | $10.03M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $2.44M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $4.81M derived: sum of 2 quarters · filed 2026-03-04 | $7.18M derived: sum of 3 quarters · filed 2026-08-06 | $10.61M 10-K · filed 2026-03-04 |
| 2025-09-30 | $2.38M 10-Q · filed 2025-11-12 | $4.74M derived: sum of 2 quarters · filed 2026-08-06 | $8.17M 10-Q · filed 2025-11-12 | $11.52M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $2.36M 10-Q · filed 2026-08-06 | $5.79M 10-Q · filed 2026-08-06 | $9.14M derived: sum of 3 quarters · filed 2026-08-06 | $12.37M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $3.43M 10-Q · filed 2026-05-12 | $6.78M derived: sum of 2 quarters · filed 2026-05-12 | $10.01M derived: sum of 3 quarters · filed 2026-05-12 | $12.87M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $3.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $6.57M derived: sum of 2 quarters · filed 2026-03-04 | $9.44M derived: sum of 3 quarters · filed 2026-03-04 | $11.46M 10-K · filed 2026-03-04 |
| 2024-09-30 | $3.23M 10-Q · filed 2025-11-12 | $6.09M derived: sum of 2 quarters · filed 2025-11-12 | $8.11M 10-Q · filed 2025-11-12 | $10.03M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $2.86M 10-Q · filed 2025-08-07 | $4.88M 10-Q · filed 2025-08-07 | $6.81M derived: sum of 3 quarters · filed 2025-08-07 | $8.75M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $2.02M 10-Q · filed 2025-05-08 | $3.94M derived: sum of 2 quarters · filed 2025-05-08 | $5.88M derived: sum of 3 quarters · filed 2025-05-08 | $7.72M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $1.92M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-24 | $3.86M derived: sum of 2 quarters · filed 2025-02-24 | $5.70M derived: sum of 3 quarters · filed 2025-02-24 | $7.05M 10-K · filed 2025-02-24 |
| 2023-09-30 | $1.94M 10-Q · filed 2024-11-07 | $3.78M derived: sum of 2 quarters · filed 2024-11-07 | $5.13M 10-Q · filed 2024-11-07 | $6.49M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $1.84M 10-Q · filed 2024-08-08 | $3.19M 10-Q · filed 2024-08-08 | $4.54M derived: sum of 3 quarters · filed 2024-08-08 | $5.91M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $1.35M 10-Q · filed 2024-05-14 | $2.71M derived: sum of 2 quarters · filed 2024-05-14 | $4.07M derived: sum of 3 quarters · filed 2024-05-14 | $5.30M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $1.36M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-29 | $2.72M derived: sum of 2 quarters · filed 2024-03-29 | $3.95M derived: sum of 3 quarters · filed 2024-03-29 | $4.76M 10-K/A · filed 2024-03-29 |
| 2022-09-30 | $1.36M 10-Q · filed 2023-11-08 | $2.59M derived: sum of 2 quarters · filed 2023-11-08 | $3.40M 10-Q · filed 2023-11-08 | $4.07M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $1.23M 10-Q · filed 2023-08-08 | $2.04M 10-Q · filed 2023-08-08 | $2.71M derived: sum of 3 quarters · filed 2023-08-08 | $3.06M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $815.00K 10-Q · filed 2023-05-11 | $1.48M derived: sum of 2 quarters · filed 2023-05-11 | $1.83M derived: sum of 3 quarters · filed 2023-05-11 | $2.16M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $669.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $1.02M derived: sum of 2 quarters · filed 2023-03-23 | $1.35M derived: sum of 3 quarters · filed 2023-03-23 | $1.53M 10-K · filed 2023-03-23 |
| 2021-09-30 | $348.00K 10-Q · filed 2022-11-10 | $677.00K derived: sum of 2 quarters · filed 2022-11-10 | $865.00K 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $329.00K 10-Q · filed 2022-08-12 | $517.00K 10-Q · filed 2022-08-12 | ||
| 2021-03-31 | $188.00K 10-Q · filed 2022-06-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |